These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. The Pathophysiological and Therapeutic Implications of Cardiac Light-Chain Amyloidosis Compared With Transthyretin Amyloidosis. Schilling JD; Nuvolone M; Merlini G JACC Heart Fail; 2024 Oct; 12(10):1781-1787. PubMed ID: 39177569 [No Abstract] [Full Text] [Related]
28. [Contribution of myocardial biopsy and immunohistochemistry to the prognostic evaluation of cardiac amyloidosis]. Van de Walle JP; Fourcade L; Panagides D; Harle JR; Pellissier JF; Touze JE; Bory M Arch Mal Coeur Vaiss; 1994 Feb; 87(2):235-9. PubMed ID: 7802531 [TBL] [Abstract][Full Text] [Related]
29. Cardiac manifestations of amyloid disease. Rivera RJ; Vicenty S Bol Asoc Med P R; 2008; 100(4):60-70. PubMed ID: 19400531 [TBL] [Abstract][Full Text] [Related]
30. A multi-modal diagnostic model improves detection of cardiac amyloidosis among patients with diagnostic confirmation by cardiac biopsy. Zhang KW; Zhang R; Deych E; Stockerl-Goldstein KE; Gorcsan J; Lenihan DJ Am Heart J; 2021 Feb; 232():137-145. PubMed ID: 33212046 [TBL] [Abstract][Full Text] [Related]
31. Transthyretin cardiac amyloidosis: an update on diagnosis and treatment. Yamamoto H; Yokochi T ESC Heart Fail; 2019 Dec; 6(6):1128-1139. PubMed ID: 31553132 [TBL] [Abstract][Full Text] [Related]
33. Cardiac Light Chain Deposition Disease Mimicking Immunoglobulin Light Chain Amyloidosis: Two Branches of the Same Tree. Osanami A; Yano T; Takemura G; Ikeda H; Inyaku M; Toda Y; Kamiyama N; Sugawara H; Gocho Y; Fujito T; Nagano N; Takahashi S; Muranaka A; Tanaka M; Moniwa N; Murase K; Takada K; Kuroda H; Ogawa Y; Miura T Circ Cardiovasc Imaging; 2020 Sep; 13(9):e010478. PubMed ID: 32873072 [No Abstract] [Full Text] [Related]
34. Severe heart failure from light chain cardiomyopathy (cardiac amyloidosis). Hofer JF; Wimmer G Z Kardiol; 2003 Jan; 92(1):90-5. PubMed ID: 12545307 [TBL] [Abstract][Full Text] [Related]
35. Diagnosis and Treatment of Cardiac Amyloidosis Related to Plasma Cell Dyscrasias. Alexander KM; Evangelisti A; Witteles RM Cardiol Clin; 2019 Nov; 37(4):487-495. PubMed ID: 31587789 [TBL] [Abstract][Full Text] [Related]
36. A rare cause of cardiac decompensation in a patient with left ventricular hypertrophy. Mangner N; Gutberlet M; Klingel K; Kandolf R; Schuler G; Linke A Clin Res Cardiol; 2012 Nov; 101(11):943-5. PubMed ID: 22645101 [No Abstract] [Full Text] [Related]
37. A review of transthyretin cardiac amyloidosis. Jhawar N; Moreno JCL; Chirila R Rom J Intern Med; 2023 Mar; 61(1):28-34. PubMed ID: 36278951 [TBL] [Abstract][Full Text] [Related]
38. The diagnosis and typing of cardiac amyloidosis. O'Hara CJ; Falk RH Amyloid; 2003 Jun; 10(2):127-9. PubMed ID: 12964421 [No Abstract] [Full Text] [Related]
40. [Progress in the diagnosis and treatment of cardiac amyloidosis]. Jurczyszyn A; Engel A; Rajzer M; Czepiel J; Mazurs G Przegl Lek; 2014; 71(6):340-5. PubMed ID: 25344976 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]